Title: CaseControl Study Design
1Case-Control Study Design
- Two groups are selected, one of people with the
disease (cases), and the other of people with the
same general characteristics but without the
disease (controls) - Compare the past exposures of both groups
2Case Control Study Design
Exposed
Diseased (Cases)
Not Exposed
Target Population
Exposed
Not Diseased (Controls)
Not Exposed
3Case-Control Study Design
- Limitations
- Cannot yield incidence rates because subjects are
selected on outcome - An estimate of the ratio of incidence rates or
risks (RR) is obtained by calculating an odds
ratio (OR)
4Odds Ratio Calculation
Outcome
Controls
Cases
Exposure
B
A
Exposed
Not Exposed
D
C
Odds Ratio
A / C
Odds of exposure for cases
Odds of exposure for controls
B / D
(estimates the relative risk)
5Comparing Odds Ratios and Relative Risks
Outcome
Controls
Cases
Exposure
370
300
70
Exposed
Not Exposed
730
700
30
1100
1000
100
OR AD/BC 5.44
RR Ie/In 4.41
6Stating your results
- OR 5.44
- Those with the disease are 5.44 times as likely
to have had the exposure compared to those
without the disease - RR 4.41
- Those with the exposure are 4.41 times as likely
to develop the disease compared to those without
the exposure
7Summary of Strengths and Limitations of
Prospective Cohort and Case-Control Studies
Case-Control
Prospective Cohort
- Strengths
- Useful for rare disease
- Relatively inexpensive
- Relatively quick results
- Strengths
- Opportunity to measure risk factors before
disease occurs - Can study multiple disease outcomes
- Can yield incidence rates as well as relative
risk estimates
- Limitations
- Possible bias in measuring risk factors after
disease has occurred - Possible bias in selecting control group
- Identified cases may not represent exposure of
all cases
- Limitations
- Useful for rare disease
- Relatively inexpensive
- Relatively quick results
8Randomized Clinical Trials(RCT)
The Gold Standard Cohort Study
9Schematic diagram of a clinical trial
Study Population
Non-participants
Participants
Randomization
Treatment arm
Control arm
Intervention or new treatment
Control
Improved
Not Improved
Not Improved
Improved
10Crossover Design
- Subjects are randomized to a sequence of two or
more treatments - Each subject serves as his own control
11Factorial Design
- Two or more treatments are evaluated
simultaneously in the same set of subjects using
varying combinations of treatments
Randomization
Placebo
Treatment A
Placebo
Treatment B
Placebo
Treatment B
12How do we evaluate whether cancer studies are
valid?
- Understand bias and confounding
13Testing for a true association
- Examine the methodology for bias
- Examine the analysis for confounding
- Examine the results for statistical significance
14Examine the study design for Bias
- Selection Bias
- Errors in the process of identifying the study
population and selecting the subjects - Information/Observation Bias
- Errors in measurements of exposure or disease
status
15Confounding
- Confounding is an apparent association between
disease and exposure caused by a third factor not
taken into consideration
16Examples of Confounders
- Study A found an association between gambling and
lung cancer. The study may be confounded by
smoking. - Study B found a larger crude death rate in
Florida than in Alaska. The rate may be
confounded by differences in the population age
structure.
17Testing for Confounding
- Calculate the crude rate
- Calculate a rate adjusted for the confounding
variable - Compare the two measures
- The two measures will be different if the
variable is a confounder (in practice, when the
crude and adjusted measures differ by at least
10)
18Expected Number of Deaths
1980 U.S. Standard Population
Population at risk
ASR
Cancer Deaths
Age
(3) x (4) (5)
(1) / (2) (3)
(4)
(2)
(1)
60,500
60,500,000
1.00 per 1000
5,000
5
0-18
0.40 per 1000
56,120
140,300,000
25,000
10
19-64
171,419
25,700,000
6.67 per 1000
15,000
100
65
288,039
xxx
45,000
115
Total
226,500,000
Crude Rate (115 / 45,000) x 1000 2.56 per 1,000
Age-Adjusted Rate (288,039 / 226,500,000) x 1000
1.27 per 1,000
Not equal
AGE IS A CONFOUNDER FOR DEATH FROM CANCER
19Evaluating Statistical Significance
- The probability that you would get your results
by chance alone is the p-value - A low p-value ( lt 0.05 ) says that chance is not
likely to explain your results - A 95 confidence interval (CI) is the range of
values in which the true value will be found 95
of the time - Large samples yield small confidence intervals
- Small samples yield large confidence intervals
20Evaluating Results
- RR 1 No difference in disease between exposed
and unexposed groups - OR 1 No difference in exposure between cases
and controls
- Examples
- RR 1.8 (1.6, 2.0) is statistically significant
- RR 1.8 (0.8, 2.9) is not statistically
significant - OR 0.7 (0.6, 0.8) is statistically significant
- OR 0.7 (0.4, 1.2) is not statistically
significant
21How do we assess whether associations between
cancer and risk factors are causal?
- Understand criteria for causality
22To Show Cause
- Chronic disease and complex conditions require
the use of Hills Postulates
- Strength of association
- Consistency of association
- Specificity of association
- Temporality
- Biologic gradient
- Plausibility
- Coherence
- Experiment
- Analogy
23How much of the morbidity and mortality from
cancer might be prevented by interventions?
- Understand the impacts of education and screening
programs
24Principles of Screening
- Validity
- Sensitivity correctly identify those with
disease - Specificity correctly identify those without
disease - Predictive Value proportion of correct
positive tests - - Predictive Value proportion of correct
negative tests - Reliability ability of test to give consistent
results - Yield amount of unrecognized disease brought to
treatment due to screening
25Calculating Measures of Validity
True Diagnosis
Total
Disease
Test Result
No Disease
ab
b
a
Positive
c
cd
d
Negative
abcd
bd
ac
Total
Positive Predictive Value a/(ab) Negative
Predictive Value d/(cd)
Sensitivity a/(ac) Specificity d/(bd)
26Example Breast Cancer Screening
Mammogram Results
Total
No Disease
Disease
1,115
983
132
Positive
63,695
63,650
45
Negative
64,810
64,633
177
Total
Sensitivity 132/177 74.6 Specificity
63,650/64,633 98.5 Positive Predictive Value
132/1,115 11.8 Negative Predictive Value
63,650/63,695 99.9
27Keys to Screening
- Sensitivity detect a sufficient number of
preclinical cases to be useful - Prevalence screen high-risk populations
- Frequency one-time screening does not allow for
differences in individual risk or differences in
onset - Participation tests unacceptable to the target
population will not be utilized - Follow-up those with positive tests need to be
provided with a plan of action
28Advice for Reading the Literature
- Identify the study design
- Understand how subjects are selected
- Understand how exposure is defined
- Evaluate potential bias and confounding
- Determine if the statistical evaluation is
appropriate - Make decisions about whether the outcome measures
are statistically significant and/or clinically
important - Use good judgment
29End